| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000036909 |
| Receipt No. | R000042062 |
| Scientific Title | A verification study of slimming effect with ingestion of the test food: a randomized, double-blind, placebo-controlled, parallel-group trial |
| Date of disclosure of the study information | 2019/05/31 |
| Last modified on | 2020/03/18 (Ver. 5) |
| Basic information | ||
| Public title | A verification study of slimming effect with ingestion of the test food | |
| Acronym | A verification study of slimming effect with ingestion of the test food | |
| Scientific Title | A verification study of slimming effect with ingestion of the test food: a randomized, double-blind, placebo-controlled, parallel-group trial | |
| Scientific Title:Acronym | A verification study of slimming effect with ingestion of the test food | |
| Region |
|
|
| Condition | |||
| Condition | Healthy Japanese subjects | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To verify the effects of 8-week-consumption of the test food on abdominal circumference. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Abdominal circumference
*Assess the measured value at screening (before consumption) and at 4 and 8 weeks after consumption or calculate the amount of change. |
| Key secondary outcomes | 1. Body weight
2. Body fat percentage 3. Muscle mass 4. Lean body mass 5. Upper arm circumference diameter 6. Thigh circumference diameter 7. Hip circumference diameter 8. Body mass index 9. Waist-to-hip ratio 10. Subjective symptoms (The Likert scale method) *1-9 Assess the measured value at screening (before consumption) and at 4 and 8 weeks after consumption or calculate the amount of change. *10 Assess the measured value at screening (before consumption) and at 4 and 8 weeks after consumption. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | YES |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | Central registration |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Duration: 8 weeks
Test food: Test food A Administration: Take 4 capsules, once per day at any time during the day. *Daily dose must be taken within the day. |
|
| Interventions/Control_2 | Duration: 8 weeks
Test food: Placebo Administration: Take 4 capsules, once per day at any time during the day. * Daily dose must be taken within the day. |
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Healthy adults
2. Japanese subjects between >=23 kg/m2 and <30 kg/m2 in body mass index (BMI) 3. Subjects who are judged as ineligible to participate in the study by the physician 4. Subjects who have relatively large abdominal circumference at screening 5. Subjects who are between >=23 kg/m2 and <25 kg/m2 in BMI or between >=25 kg/m2 and <30 kg/m2 in BMI with <85 cm for men and <90cm for women in the abdominal circumference at screening |
|||
| Key exclusion criteria | 1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure or myocardial infarction
2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Currently undergoing treatment for any of the following chronic disease: cardiac arrhythmia, liver disorder, kidney disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, obesity or any other chronic diseases 4. Subjects who use or take "Foods for Specified Health Uses", "Foods with Functional Claims", or other functional food/beverage in daily 5. Subjects who are currently taking medications (including herbal medicines) and supplements 6. Subjects who are allergic to medicines and/or the test food related products 7. Subjects who are allergic to citrus fruits. 8. Subjects who are pregnant, lactation, or planning to become pregnant 9. Subjects who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial or plan to participate another trial during this trial 10. Subjects who are judged as ineligible to participate in the study by the physician |
|||
| Target sample size | 40 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | ORTHOMEDICO Inc. | ||||||
| Division name | CEO | ||||||
| Zip code | 112-0002 | ||||||
| Address | 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan. | ||||||
| TEL | 03-3818-0610 | ||||||
| kazu@orthomedico.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | ORTHOMEDICO Inc. | ||||||
| Division name | R&D Department | ||||||
| Zip code | 112-0002 | ||||||
| Address | 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan. | ||||||
| TEL | 03-3818-0610 | ||||||
| Homepage URL | |||||||
| nao@orthomedico.jp | |||||||
| Sponsor | |
| Institute | ORTHOMEDICO Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Toyo Sugar Refining Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Medical Corporation Seishinkai, Takara Clinic |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | The ethical committee of the Takara Clinic, Medical Corporation Seishinkai |
| Address | 9F Taisei Building, 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan. |
| Tel | 03-5793-3623 |
| info@takara-clinic.com | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 44 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042062 |